Cosmos Health’s C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales in the UK and Greece with gross margins above 70%. The company aims for $7.4 million revenue and $5.3 million gross profit in three years through EU market expansion and animal healthcare entry.
C-Scrub and C-Sept generated over $1.5 million in combined annualized sales in the UK and Greece, with nearly half coming from the UK market. Both brands achieve gross margins above 70% and have built strong adoption through e-commerce channels and hospital distribution.
Cosmos Health projects C-Scrub and C-Sept revenue to rise from $2.5 million in 2026 to $7.4 million by 2028, with gross profit increasing from $1.8 million to $5.3 million over that period. These targets assume sustained margins near 72% and continued market penetration.
The company plans to expand the antiseptic brands into additional EU countries, professional hygiene and clinical settings, and the animal healthcare market, potentially broadening its addressable market and driving upward revisions to its targets.
